Buchumschlag

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Adam S. Faye, Jordan Axelrad, Jiangwei Sun, Jonas Halfvarsson, Par Myrelid, Jonas Söderling, Ola Olén, Jonas F. Ludvigsson
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021
von: Mehdi Osooli, et al.
Veröffentlicht: (2025)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
von: Carl Eriksson, et al.
Veröffentlicht: (2024)

Antibiotic Use and Risk of Microscopic Colitis in Older Adults: A Nationwide Self‐Controlled Case Series Study
von: Máté Szilcz, et al.
Veröffentlicht: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
von: Kyle Staller, et al.
Veröffentlicht: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
von: David Bergman, et al.
Veröffentlicht: (2024)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
von: Máté Szilcz, et al.
Veröffentlicht: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
von: Catherine Z. Tang, et al.
Veröffentlicht: (2025)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
von: Katherine L. Stone, et al.
Veröffentlicht: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
von: Maria Ling Lundström, et al.
Veröffentlicht: (2024)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
von: Jakob B. Seidelin
Veröffentlicht: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
von: Xinli Chen, et al.
Veröffentlicht: (2024)

Early‐Life Infections, Antibiotics and Later Risk of Childhood and Early Adult‐Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts
von: Karl Mårild, et al.
Veröffentlicht: (2024)

Editorial: Remission Ambition—How Far Should We Push in Older Adults? Authors' Reply
von: Catherine Z. Tang, et al.
Veröffentlicht: (2025)

Editorial: Getting to the Heart of the Matter in IBD
von: Ashwin N. Ananthakrishnan
Veröffentlicht: (2025)

Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study
von: Laurent Lam, et al.
Veröffentlicht: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
von: Ramin Ebrahimi, et al.
Veröffentlicht: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
von: Daniele Noviello, et al.
Veröffentlicht: (2025)

Women's Health Disorders in a Coeliac Disease Population After Diagnosis—A Nationwide Cohort Analysis
von: Rama Nanah, et al.
Veröffentlicht: (2025)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
von: Seogsong Jeong, et al.
Veröffentlicht: (2026)

Letter: Addressing opioid exposure and associated harms in patients with IBD
von: Christian P. Selinger, et al.
Veröffentlicht: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
von: Guofu Mao, et al.
Veröffentlicht: (2026)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
von: Saad Khan, et al.
Veröffentlicht: (2024)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
von: Simone Chin, et al.
Veröffentlicht: (2025)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
von: Darcy Quinn Holt, et al.
Veröffentlicht: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
von: James L. Alexander, et al.
Veröffentlicht: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
von: Parul Tandon, et al.
Veröffentlicht: (2025)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
von: Xueneng Yang, et al.
Veröffentlicht: (2025)

Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population‐Based Cohort Study
von: Samantha Baillie, et al.
Veröffentlicht: (2025)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
von: Keith Bodger
Veröffentlicht: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
von: Alice S. Day, et al.
Veröffentlicht: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
von: Giovanni Cammarota, et al.
Veröffentlicht: (2024)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
von: Shabari Shenoy, et al.
Veröffentlicht: (2025)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
von: Fahim Ebrahimi, et al.
Veröffentlicht: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
von: Olga M. Nardone, et al.
Veröffentlicht: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
von: Samantha Baillie, et al.
Veröffentlicht: (2025)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
von: Chachrit Khunsriraksakul, et al.
Veröffentlicht: (2025)